-+ 0.00%
-+ 0.00%
-+ 0.00%

Benitec Biopharma Q1 FY27 net loss widens 44% year over year to $12.93 million

PUBT·11/13/2026 13:02:06
Listen to the news
Benitec Biopharma Q1 FY27 net loss widens 44% year over year to $12.93 million
  • Benitec Biopharma’s FY27 first-quarter net loss widened 44% year over year to $12.93 million.
  • Research and development expenses more than doubled to $8.62 million, while total operating expenses rose 48% year over year to $14.48 million.
  • Cash and cash equivalents totaled $176.37 million at September 30, 2026.
  • BB-301 interim results showed a 100% responder rate across both cohorts, with no serious adverse events reported in treated patients.
  • The BB-301 pivotal trial remains on track to begin in mid-2027, with study-design confirmation expected in the first calendar quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130800PRIMZONEFULLFEED9877003) on November 13, 2026, and is solely responsible for the information contained therein.